professionals in evaluating their patients and independently assessing their skin. Belle.ai’s technology also proposes objective scoring for standard assessments of immune-mediated skin disorders (psoriasis, eczema, alopecia areata, vitiligo) for patients already diagnosed with these conditions to help healthcare professionals track progression over time.

Belle.ai’s software is used as a reference tool by providers including Federally Qualified Health Centers, emergency departments and community hospitals. Researchers in low- and middle-income countries around the globe use Belle.ai’s technology to study rare and neglected tropical diseases. Pharmaceutical companies rely on Belle.ai to evaluate their therapeutics through objective image assessment of treatment progression.

Belle.ai’s software offerings are not intended to diagnose, treat, cure, or mitigate any disease or condition, and are intended only to assist healthcare professionals in attending to their patients using their independent medical judgment.